Owlet, Inc.
NYSE:OWLTMedical - Devices
+$0.46 today
- Market cap
- $107.24M
- Beta
- 1.86
- P/E (TTM)
- -0.4
- EPS (TTM)
- -$12.67
Volume 0.64M
Average 0.24M
OWLT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Owlet, Inc.NYSE: OWLT
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $3.49M rose 110.6% year over year, ahead of the +38.7% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 27.8% from the prior quarter. Over 3 fiscal years it compounded at -10.1% a year.
Context
- Stock-based compensation amounted to 8.8% of revenue in FY2025, down 2.2 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +110.6% holds above the trailing-twelve-month pace of +38.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 9.35M USD
- Year-over-year change
- +8.3%
- 4-year CAGR
- +21.7%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.35M | +8.3% |
| FY2024 | 2024-12-31 | 8.63M | -13.1% |
| FY2023 | 2023-12-31 | 9.93M | -22.7% |
| FY2022 | 2022-12-31 | 12.86M | +201.9% |
| FY2021 | 2021-12-31 | 4.26M | — |
Stock-Based Compensation vs competitors
How OWLT compares with its peers on the latest reported figures
- OWLT's LTM Mar 2026 stock-based compensation of $11.18M is the 3rd largest of the 10 companies compared; the peer median is $4.48M.
- Its year-over-year change of +38.7% is the 3rd highest of 10, against a peer median of +10.0%.
- Stock-based compensation amounts to 10.4% of revenue for OWLT, versus a peer median of 12.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $2.3B | +49501.8% | -33.1% | 44751.8% | |
| LTM Mar 2026 | $13.86M | +11.8% | -11.0% | 11.9% | |
| LTM Mar 2026 | $11.18M | +38.7% | -10.1% | 10.4% | |
| LTM Mar 2026 | $6.49M | -5.6% | +3.2% | — | |
| LTM Mar 2026 | $5.99M | +19.7% | +10.2% | 1140.6% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $4.48M | -15.1% | +38.4% | 241.9% |
| LTM Mar 2026 | $4.21M | +10.0% | +0.1% | 12.3% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $3.05M | +83.8% | +67.0% | — |
| LTM Mar 2026 | $2.49M | -6.7% | -22.0% | 4.3% | |
| LTM Mar 2026 | $706K | -76.8% | — | 2.2% | |
| Peer median (excluding OWLT) | $4.48M | +10.0% | +1.7% | 12.3% | |
Competitors are the stored peer set for OWLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.7M) | (79.34M) | (32.9M) | (12.54M) | (38.46M) |
| Depreciation & Amortization | 1.13M | 2.67M | 2.21M | 1.38M | 590K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.26M | 12.86M | 9.93M | 8.63M | 9.35M |
| Change in Working Capital | 9.45M | (15.2M) | (4.82M) | (2.52M) | (10.71M) |
| Accounts Receivables | (144K) | (8.5M) | 965K | 2.03M | (10.97M) |
| Inventory | (11.65M) | (1.18M) | 12.12M | (4.14M) | (4.93M) |
| Accounts Payables | 32.12M | (10.72M) | (19.5M) | 1.32M | 5.43M |
| Other Working Capital | (10.87M) | 5.2M | 1.6M | (1.74M) | (236K) |
| Other Non-Cash Items | 16.3M | (2.37M) | 2.05M | (6.16M) | 28.43M |
| Operating Cash Flow | (40.56M) | (81.38M) | (23.53M) | (11.21M) | (10.8M) |
| Capital Expenditures | (2.02M) | (1.57M) | (59K) | (761K) | (273K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (1.05M) | (929K) | (43K) | (726K) | 0 |
| Investing Cash Flow | (2.02M) | (1.57M) | (59K) | (761K) | (943K) |
| Debt Repayment | (3.49M) | (1.5M) | 156K | (816K) | 55K |
| Common Stock Issued | 0 | 0 | 0 | 10M | 34.69M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 124.11M | 618K | 269K | (2M) | (2.64M) |
| Financing Cash Flow | 120.62M | (878K) | 28.91M | 16.04M | 32.1M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 78.05M | (83.82M) | 5.33M | 4.07M | 20.38M |
| Free Cash Flow | (42.58M) | (82.95M) | (23.59M) | (11.97M) | (11.07M) |
Owlet, Inc.
NYSE:OWLT
Intrinsic Alpha fair value
Locked
Current Price
$3.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.